#161791

vRRP3 cell line

Cat. #161791

vRRP3 cell line

Cat. #: 161791

Organism: Human

Tissue: Skin

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Christoper Stipp

Institute: University Of Iowa Research Foundation

Primary Citation: Zhu et al. 2022. npj Precis. Onc. PMID: 36271142

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: vRRP3 cell line
  • Alternate name: vRRP3
  • Parental cell: A375 Melanoma (ATCC)
  • Organism: Human
  • Gender: Female
  • Tissue: Skin
  • Donor: A375 (ATCC) -human melanoma cell line of a solid tumor from a 54-year-old female.
  • Morphology: Diffuse Morphology
  • Description: Drug-resistant sub-lines of A375 that are BRAF^V600E and NRAS WT. VRPP3 Harbours RAC1^N921 but does not harbour NRAS mutations or BRAF genomic alterations, which drive drug resistance through MAPK-reactivation. It is a VEM-resistant derivative of A375. vRPP3 served as a positive control as it harbours a heterozygous N92I mutation in RAC1, con?rmed via Sanger sequencing. Shows Increased VAV1 protein levels. Showed decreased MEK Phosphorylation on S217(Raf Site) and Increased MEK Phosphoryla...
  • Production details: Spontaneous vemurafenib-resistant clones and populations were created after 2–3 and 4–6 weeks cultured in 3 mm vemurafenib. maintained in media with 3 mm vemurafenib.

Handling

  • Growth medium: DMEM(Gibco) suplemented with penicillin/streptomycin (Gibco) and 10% FBS (Gibco).

References

  • Feddersen et al.2019. Cancer Res. 79(19).PMID: 31416844